An anonymous director reports

RAKOVINA THERAPEUTICS ANNOUNCES UPSIZED FINANCING UP TO $2.0 MILLION

Rakovina Therapeutics Inc.'s previously announced financing has been upsized up to approximately $2-million.

On Jan. 27, the company announced that it has reached an agreement in principle with an existing investor to invest an additional $1.0-million in the company by way of a non-brokered private placement of an unsecured convertible debenture and two million common share purchase warrants. The company anticipates that key terms of the convertible debenture would include:

• A maturity date of Jan. 28, 2029;
• A conversion price of 20 cents per common share;
• An interest rate of 12 per cent per annum, payable semi-annually in cash.

Each warrant would be exercisable at 20 cents per common share until Jan. 28, 2029, subject to customary adjustments. A subsequent news release will be issued in connection with the debenture private placement once financing terms have been finalized.

Concurrently with the debenture private placement, the company proposes to offer up to 8,333,334 common shares at a price of 12 cents per share for additional gross proceeds of up to approximately $1.0-million by way of a non-brokered private placement. As consideration for services provided in connection with the common share private placement, the company may pay finders' fees to certain eligible finders who introduce subscribers to the financing.

The terms of the private placements, as announced in the company's news release dated Jan. 27, 2026, otherwise remain unchanged.

The company intends to use the aggregate gross proceeds of the private placements to provide near-term working capital to support continuing corporate activities and strategic initiatives while the company continues to evaluate longer-term financing alternatives.

Closing of the private placements is subject to the company obtaining all necessary corporate and regulatory approvals, including approval of the TSX Venture Exchange, and entry into definitive subscription agreements. Pursuant to applicable Canadian securities laws, all securities issued in connection with the private placements will be subject to a statutory hold period of four months plus a day from the date of issuance.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. The company's work is based on unique technologies for targeting the DNA-damage response powered by artificial intelligence (AI) using the proprietary Deep-Docking and Enki platforms. By using AI, the company can review and optimize drug candidates at a much greater pace than ever before.

The company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

We seek Safe Harbor.